HIV and Hepatitis.com Coverage of the
58th Annual Meeting of the American Association
for the Study of Liver Diseases (AASLD 2007)
November 2-6, 2007, Boston, MA

Library of Slides and Posters
• Pegylated Interferon + ribavirin

Hepatitis C Articles
Hepatitis B Articles
HIV-HCV or HIV-HBV Coinfection Articles

 

 

Hepatitis C Articles               Top
Experimental Polymerase Inhibitor HCV-796 is Safe and Effective in Combination with PegIntron or Pegasys
Novel HCV Polymerase Inhibitor VCH-759 Monotherapy Demonstrates Promising Antiviral Activity
Polymerase Inhibitor NM107 and Protease Inhibitor Boceprevir Show Enhanced Anti-HCV Activity in Combination
Anti-HCV and Anti-fibrotic Effects of Drugs Used for Other Indications
Experimental Botanical Therapies for Hepatitis C
Different Treatment Outcomes among Individuals Infected with the Same Strain of HCV
Liver Stiffness Measurement (FibroScan) More Useful for Assessing Fibrosis in Patients with HCV Compared with HBV
New Controlled-release Interferon Alfa (Locteron) Demonstrates Promising Activity against HCV
Depression Due to Treatment with Pegylated Interferon plus Ribavirin May Be Under-diagnosed by Clinicians
How Effective Is Pegylated Interferon plus Ribavirin for HCV Genotype 1 Patients Over Age 50?
Pegylated Interferon Alfa-2a (Pegasys) plus Ribavirin for Patients with HBV and HCV Coinfection
Prophylaxis with Pegylated Interferon Alfa-2a (Pegasys) plus Ribavirin vs No Prophylaxis after Liver Transplantation
Is Pegylated Interferon Alfa-2a (Pegasys) plus Ribavirin Superior to High-dose Consensus Interferon (Infergen) plus Ribavirin?
Epidemiology and Treatment Response of Genotype 5 HCV; Researchers Find New Seventh Genotype
Induction with High-dose Pegylated Interferon alfa-2a (Pegasys) Is More Effective than Standard Dosing for Achieving Rapid and Early Virological Response: The CHARIOT Study
Assessment of HCV RNA at Week 4 and Week 12 Optimizes Prediction of Treatment Outcomes in HCV Patients Treated with Pegylated Interferon Alfa-2b (PegIntron) plus Ribavirin
Viral Kinetics Can Quickly Predict Sustained Virological Response in Hepatitis C Patients with Normal ALT Treated with PegIntron plus Ribavirin
HALT-C Trial Shows Minimal Long-term Benefit of Pegylated Interferon Alfa-2b (Pegasys) Maintenance Therapy in Patients with Chronic Hepatitis C
Long-term, Low-Dose Treatment with Pegylated Interferon Alfa-2b (PegIntron) Monotherapy Leads to a Reduction in Fibrosis and Inflammatory Scores in Prior Non-responders
Treatment with Low-dose Pegylated Interferon Alfa-2b (PegIntron) Does Not Adversely Affect Quality of Life over a 2-year Period: The COPILOT Trial
Rapid Virological Response at Week 4 Is the Best Predictor of Treatment Outcome in Patients with Chronic Hepatitis C
Some Chronic Hepatitis C Patients Failing Prior Interferon/Ribavirin Achieve Sustained Virological Response with Albinterferon Alfa-2b
Consensus Interferon Produces Sustained Response in Some Non-responders and Relapsers to Prior Interferon-based Therapy
Interim Data Show Nitazoxanide (Alinia) Improves Anti-HCV Activity When Added to Pegylated Interferon plus Ribavirin
Highly Sensitive HCV RNA Tests Required to Evaluate Treatment Response and Relapse Rates and to Create Individualized Treatment Strategies for Hepatitis C Patients
Early Treatment Is Indicated for Patients with Chronic Hepatitis C Regardless of Body Weight
Future Studies Should Avoid Combining Genotype 2 and Genotype 3 Patients Due to Lower Response Rate in the Genotype 3 Population
Ultra Rapid Virological Response at Week 2 Predicts Sustained Response in HCV Genotype 3 Patients with High Viral Load: The Get-C Study
Combination Therapy with HCV Protease Inhibitor Telaprevir (VX-950) plus Pegylated Interferon and Ribavirin Produces Sustained Response in 61% of Genotype 1 Patients
Experimental Roche Polymerase Inhibitor R1626 Shows Robust Synergistic Effect in Combination with Pegylated Interferon with or without Ribavirin
Pegylated Interferon Alfa-2a (Pegasys) plus Ribavirin in Non-responders to Pegylated Interferon Alfa-2b (PegIntron) plus Ribavirin: Final Results of the REPEAT Trial
Final Results of the Canadian Pegylated Interferon Alfa-2b (PegIntron) Prospective Optimal Weight-based Dosing Response (POWeR) Study
Assessment of Viral Kinetics Helps Predict Response to Treatment with Pegylated Interferon Alfa plus Ribavirin in Chronic Hepatitis C Patients
Combination Therapy with HCV Protease Inhibitor Telaprevir (VX-950) plus Pegylated Interferon and Ribavirin Produces Sustained Response in 61% of Genotype 1 Patients
Experimental Roche Polymerase Inhibitor R1626 Shows Robust Synergistic Effect in Combination with Pegylated Interferon with or without Ribavirin
Pegylated Interferon Alfa-2a (Pegasys) plus Ribavirin in Non-responders to Pegylated Interferon Alfa-2b (PegIntron) plus Ribavirin: Final Results of the REPEAT Trial
Final Results of the Canadian Pegylated Interferon Alfa-2b (PegIntron) Prospective Optimal Weight-based Dosing Response (POWeR) Study
Assessment of Viral Kinetics Helps Predict Response to Treatment with Pegylated Interferon Alfa plus Ribavirin in Chronic Hepatitis C Patients
Study Finds Strong Association Between Hepatitis C and Tattooing; HCV Testing Recommended for All People with Tattoo

Phase 1b Study Shows Toll-like Receptor 9 Agonist CPG 10101 Decreases HCV RNA in Patients with Chronic Hepatitis C

 

.
Hepatitis B Articles                Top
Effect of Lamivudine (Epivir-HBV) and Adefovir (Hepsera) in Preventing Hepatocellular Carcinoma
Impact of Adefovir (Hepsera) on Liver Fibrosis and Histological Activity Assessed Using FibroTest-ActiTest in Hepatitis B Patients
Chronic Hepatitis B Patients May Have Significant Liver Disease Despite Normal ALT
Liver Stiffness Measurement (FibroScan) More Useful for Assessing Fibrosis in Patients with HCV Compared with HBV
Preemptive Lamivudine Therapy Reduces Risk of Liver Disease Flares in Hepatitis B Patients Starting Cancer Chemotherapy
Pegylated Interferon Alfa-2a (Pegasys) plus Ribavirin for Patients with HBV and HCV Coinfection
New Data on Telbivudine (Tyzeka) for Treatment of Chronic Hepatitis B
Decline in Number of Patients Requiring Liver Transplants Due to Hepatitis B
Predictors and Long-term Outcomes Associated with Hepatitis B Surface Antigen (HBsAg) Clearance
Chronic Hepatitis B Patients with Low HBV Viral Load Still Have an Elevated Risk of Liver Cancer: R.E.V.E.A.L.-HBV Study
Gender Difference in the Natural Course of HBeAg-Positive Chronic Hepatitis B
Tenofovir (Viread) Is Superior to Adefovir (Hepsera) at 48 Weeks for Both HBeAg Positive and HBeAg Negative Patients with Chronic Hepatitis B
Entecavir (Baraclude) Maintains HBV Suppression through 4 Years in Nucleoside-naive HBeAg Positive Patients
Entecavir (Baraclude) Maintains HBV Suppression through 4 Years in Nucleoside-naive HBeAg Positive Patients
12 Weeks of Pegylated Interferon Works as Well as 48 Weeks in Selected Patients with HBeAg Positive Chronic Hepatitis B

Hepatitis B Virus DNA Found in 16th Century Mummy in Korea.


HIV-HCV / HIV-HBV Articles               Top
Liver Enzyme Elevation and Immune Reconstitution in HIV Patients with and without Hepatitis B or C Coinfection
Early Anti-HCV Activity of Pegasys and PegIntron Are Similar in HIV-HCV Coinfected Patients
Sexual Transmission of HCV among HIV Positive Men Who Have Sex with Men in France
Weight-based Ribavirin Increases Sustained Response Rate among HIV-HCV Coinfected Genotype 1 Patients, but also Raises Risk of Anemia
Biological Mechanisms Underlying Accelerated Liver Disease Progression in HIV-HCV Coinfected Individuals
Similar Response Rates and Disease Progression in HIV-HCV Coinfected and HCV Monoinfected Patients
Retreatment with Pegylated Interferon alfa-2a (Pegasys) plus Weight-based Ribavirin in HIV-HCV Coinfected Non-responders and Relapsers to Prior Hepatitis C Treatment: The PILOT-NR Study
Treatment with Interferon-based Therapy Reduces the Risk of End-stage Liver Disease in HIV-HCV Coinfected Patients
Boosted Fosamprenavir (Lexiva) Linked to Increased Anti-HCV Immune Response and Lower HCV Viral Load in HIV-HCV Coinfected Patients
Abacavir (Ziagen) in HAART Regimen May Reduce Response to Hepatitis C Treatment in Coinfected Individuals
HIV-HBV Coinfected Liver Transplant Recipients Have Outcomes Similar to Those of HIV Negative Patient
HIV-HCV Coinfected Individuals Less Likely to Spontaneously Clear HCV During Acute Infection

 

Unless otherwise stated, all references are to the Abstracts of the 58th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD).

Please note that the material published here by HIV and Hepatitis.com about the 58th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) is not approved by nor is it a part of AASLD.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 
 
 
 

 

 

 

 

 




BOSTON, MA


Sponsors